IGNK 001
Alternative Names: IGNK 001 - Gengleucel; IGNK-001Latest Information Update: 20 May 2024
At a glance
- Originator Ingenium Therapeutics
- Class Antineoplastics; Immunotherapies; Natural killer cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Acute myeloid leukaemia
Most Recent Events
- 30 Apr 2024 Phase-II clinical trials in Acute myeloid leukaemia (Second-line therapy or greater) in South Korea (Parenteral) before April 2024
- 30 Apr 2024 IGNK 001 receives Orphan Drug status for Acute myeloid leukaemia in USA
- 30 Apr 2024 Korean Ministry of Food and Drug Safety approves regulatory application for IGNK 001 for phase II clinical trials in Acute myeloid leukemia before April 2024